Cancer Biomarkers Market Report

• Thermo Fisher Scientific Inc. (US) received US FDA approval for the Oncomine Dx Express Test when run on its Ion Torrent Genexus Dx integrated sequencer. This test serves as a companion diagnostic (CDx) for Dizal’s Zegfrovy (sunvozertinib), specifically identifying patients with non-small cell lung cancer (NSCLC) having EGFR exon 20 insertion mutations. It is also approved for broader solid tumour profiling across 46 genes. (July 5, 2025)
• Illumina Inc (US) acquired Soma Logic, Inc (US) for $350M, to integrate its aptamer-based proteomics technology (SomaScan) with Illumina’s NGS platforms and multiomics strategy. This aims to enhance biomarker discovery and disease profiling in cancer by enabling large-scale protein marker analysis alongside genomic data. (June 23, 2025)
• Agilent Technologies, Inc. (US) partnered with Ubix Therapeutics Co., Ltd (South Korea) to jointly research and develop targeted cancer therapies using Targeted Protein Degradation (TPD) and Antibody-Drug Conjugates (ADCs) in South Korea. This collaboration leverages Ubix’s Degraducer® platform and Agilent’s analytical technologies (like LC/MS and BioTek) to advance these promising modalities, aiming to address difficult cancer targets and potentially improve patient outcomes, representing progress in the development of next-generation precision oncology treatments.(May 14, 2025)
• QIAGEN N.V. (Germany) partnered with Element Biosciences Inc. (US) to integrate its QIAseq xHYB CGP Panels onto the AVITI platform, aiming to make cancer genomic profiling faster, easier, and more cost-effective, thereby improving biomarker testing efficiency; they also partnered with Myriad Genetics Inc. (US) to launch a global sequencing-based HRD assay designed for deeper insights into DNA repair deficiencies to optimize treatment strategies, and introduced HSMD Research as a free database to enhance data accessibility for academic researchers studying key cancer genes. (April 23, 2025)

Drivers: Rising Global Incidence and Prevalence of Cancer

The fundamental driver for the cancer biomarkers market is the relentless increase in the global burden of cancer. More cancer cases translate directly into a greater need for effective diagnostics, prognostics, and monitoring tools. Cancer biomarkers are increasingly recognized as essential for achieving earlier detection, accurate diagnosis, and guiding personalized treatment strategies, thereby improving patient outcomes. This escalating disease burden creates a massive and growing demand for biomarker-based solutions across the healthcare system.

For instance, in 2022 alone, approximately 20 million new cancer cases were diagnosed worldwide, leading to nearly 10 million deaths. This left an estimated 53.5 million cancer survivors living for at least five years post-diagnosis. The global cancer landscape is expected to worsen, with new case numbers projected to exceed 35 million annually by 2050. This represents a significant increase from current levels. The sheer scale of the cancer problem necessitates innovative solutions like biomarkers. Health systems worldwide are under pressure to improve detection rates and treatment efficacy, making biomarkers a critical component of modern oncology. This driver creates a persistent and expanding market need.

Opportunities: Technological Advancements and the Expansion of Personalized Medicine.

Rapid advancements in technologies such as Next-Generation Sequencing (NGS), liquid biopsy, proteomics, metabolomics, and Artificial Intelligence (AI) are revolutionizing the cancer biomarkers field. These technologies enable the discovery of more sensitive, specific, and comprehensive biomarkers. Furthermore, they facilitate the integration of biomarker data into clinical workflows to support personalized medicine – tailoring cancer prevention, detection, and treatment strategies to individual patient characteristics and tumour profiles. This shift towards precision oncology is creating vast new opportunities.
The market is rapidly evolving; close to 100 novel cancer biomarker solutions leveraging NGS and AI-driven analysis pipelines are already commercially available. This demonstrates the tangible impact of technological innovation. The pipeline with over 685 ongoing clinical trials actively investigating novel biomarkers. Moreover, a significant trend is evident where more than 70% of recently launched cancer biomarker solutions are designed to support personalized risk assessment and therapy selection.

Challenges: High Costs and Complexities in Biomarker Discovery, Validation, and Commercialization

Despite their potential, the development and deployment of cancer biomarkers face significant financial and logistical hurdles. The process from initial discovery to validated, clinically approved, and commercially available test is long, complex, and extremely expensive. This involves extensive research, multi-center clinical validation studies, stringent regulatory approvals, and complex manufacturing processes. The high-cost acts as a major barrier, particularly impacting smaller biotech firms and limiting access in low- and middle-income countries (LMICs).

For instance, established biomarker tests carry significant costs. For example, HER2 testing, crucial for breast cancer treatment decisions, averages around $320 per test in the USA, $280 in Germany, and $150 in India. While costs vary, advanced multi-gene panel tests can cost several hundred to over a thousand dollars. The cumulative cost of development, coupled with often uncertain reimbursement policies, significantly restricts market access. This is particularly evident outside major markets like North America and Western Europe, where healthcare systems may be less able to afford or reimburse these advanced diagnostics

The global cancer biomarkers market is pivotal in modern oncology, driving diagnostics, treatment personalization, and disease monitoring. Valued at approximately USD 24.2 billion in 2024, this market is projected for high growth, potentially reaching over USD 43.3 billion by 2030, indicating a CAGR of roughly 10.2%. This expansion is fundamentally fueled by the escalating global cancer incidence, with over 20 million new cases annually creating a critical need for advanced diagnostics.
Significant opportunities emerge from technological breakthroughs such as NGS, AI, and liquid biopsy, which are revolutionizing personalized medicine approaches. However, substantial challenges persist, primarily the high costs associated with the complex processes of biomarker discovery, rigorous validation, and clinical implementation. These financial burdens can hinder accessibility, particularly in resource-limited settings, and slow market penetration despite the clear clinical benefits offered by biomarker-based strategies. The market encompasses diverse biomarker applications, from early detection and prognosis to therapy selection and monitoring, forming the backbone of precision oncology efforts worldwide.